Reviva Pharmaceuticals Holdings, Inc. (RVPH): Price and Financial Metrics

Reviva Pharmaceuticals Holdings, Inc. (RVPH): $3.09

0.07 (+2.32%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add RVPH to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#327 of 360

in industry

RVPH Price/Volume Stats

Current price $3.09 52-week high $9.25
Prev. close $3.02 52-week low $2.67
Day low $2.95 Volume 111,500
Day high $3.15 Avg. volume 315,792
50-day MA $3.65 Dividend yield N/A
200-day MA $4.28 Market Cap 86.27M

RVPH Stock Price Chart Interactive Chart >


Reviva Pharmaceuticals Holdings, Inc. (RVPH) Company Bio


Reviva Pharmaceuticals Holdings, Inc. operates as a clinical development pharmaceutical company. The Company focuses on developing a portfolio of internally discovered therapies that address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases. Reviva Pharmaceuticals Holdings serves customers worldwide.


RVPH Latest News Stream


Event/Time News Detail
Loading, please wait...

RVPH Latest Social Stream


Loading social stream, please wait...

View Full RVPH Social Stream

Latest RVPH News From Around the Web

Below are the latest news stories about REVIVA PHARMACEUTICALS HOLDINGS INC that investors may wish to consider to help them evaluate RVPH as an investment opportunity.

Karuna downgraded, Arm target raised: Wall Street's top analyst calls

Karuna downgraded, Arm target raised: Wall Street's top analyst calls

Yahoo | December 26, 2023

Life Science Investor Forum: Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Investor Forum sponsored by Zacks Small-Cap Research. held December 14th are now available for online viewing. REGISTER NOW AT: https://bit.ly/41oBqxg The company presentations will be available 24/7 for 90 days. Investors, adv

Yahoo | December 15, 2023

Life Science Investor Forum Agenda Announced for December 14th, 2023

NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum to be held December 14th. This event is sponsored by Zacks Small-Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/3tcvQkSIt is recommended that investors pre-register and run the online system check to expedite participat

Yahoo | December 12, 2023

Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum

CUPERTINO, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, will participate live at the Life Sciences Investor Forum, hosted by VirtualInvestorConferen

Yahoo | December 11, 2023

Reviva Pharmaceuticals to Participate in The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

CUPERTINO, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO, and Narayan Prabhu, CFO of Reviva, will participate in The Benchmark Company’s Discovery One-on-One In

Yahoo | November 30, 2023

Read More 'RVPH' Stories Here

RVPH Price Returns

1-mo 6.92%
3-mo -20.57%
6-mo -18.47%
1-year -52.75%
3-year -28.47%
5-year N/A
YTD -40.00%
2023 21.18%
2022 47.06%
2021 -66.95%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!